Vanguard Group
SNDX icon

Vanguard Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Vanguard Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$131M Buy
6,230,334
+1,091,717
+21% +$19M ﹤0.01% 1745
2025
Q3 		$79.1M Buy
5,138,617
+104,683
+2% +$1.37M ﹤0.01% 1957
2025
Q2 		$47.1M Buy
5,033,934
+162,869
+3% +$1.79M ﹤0.01% 2145
2025
Q1 		$59.8M Sell
4,871,065
-10,903
-0.2% -$154K ﹤0.01% 2019
2024
Q4 		$64.5M Sell
4,881,968
-5,006
-0.1% -$85.7K ﹤0.01% 2054
2024
Q3 		$94.1M Buy
4,886,974
+89,885
+2% +$1.86M ﹤0.01% 1897
2024
Q2 		$98.5M Sell
4,797,089
-129,895
-3% -$2.72M ﹤0.01% 1845
2024
Q1 		$117M Buy
4,926,984
+591,631
+14% +$13.2M ﹤0.01% 1780
2023
Q4 		$93.7M Buy
4,335,353
+718,051
+20% +$11M ﹤0.01% 1898
2023
Q3 		$52.5M Buy
3,617,302
+34,632
+1% +$655K ﹤0.01% 2114
2023
Q2 		$75M Buy
3,582,670
+85,585
+2% +$1.78M ﹤0.01% 2012
2023
Q1 		$73.9M Buy
3,497,085
+133,635
+4% +$3.32M ﹤0.01% 1977
2022
Q4 		$85.6M Buy
3,363,450
+561,151
+20% +$13.1M ﹤0.01% 1887
2022
Q3 		$67.3M Buy
2,802,299
+21,396
+0.8% +$480K ﹤0.01% 2032
2022
Q2 		$53.5M Buy
2,780,903
+348,465
+14% +$5.8M ﹤0.01% 2165
2022
Q1 		$42.3M Buy
2,432,438
+95,068
+4% +$1.6M ﹤0.01% 2386
2021
Q4 		$51.2M Buy
2,337,370
+167,964
+8% +$3.1M ﹤0.01% 2334
2021
Q3 		$41.5M Buy
2,169,406
+60,658
+3% +$1.01M ﹤0.01% 2461
2021
Q2 		$36.2M Buy
2,108,748
+37,800
+2% +$692K ﹤0.01% 2538
2021
Q1 		$46.3M Buy
2,070,948
+219,115
+12% +$4.95M ﹤0.01% 2362
2020
Q4 		$41.2M Buy
1,851,833
+454,748
+33% +$9.43M ﹤0.01% 2307
2020
Q3 		$20.6M Sell
1,397,085
-35,455
-2% -$540K ﹤0.01% 2443
2020
Q2 		$21.2M Buy
1,432,540
+353,812
+33% +$5.39M ﹤0.01% 2395
2020
Q1 		$11.8M Buy
1,078,728
+9,141
+0.9% +$85.8K ﹤0.01% 2538
2019
Q4 		$9.39M Sell
1,069,587
-2,561
-0.2% -$18.8K ﹤0.01% 2888
2019
Q3 		$8.01M Buy
1,072,148
+42,998
+4% +$392K ﹤0.01% 2929
2019
Q2 		$9.58M Buy
1,029,150
+80,761
+9% +$589K ﹤0.01% 2881
2019
Q1 		$4.98M Buy
948,389
+99,747
+12% +$569K ﹤0.01% 3146
2018
Q4 		$3.78M Buy
848,642
+112,038
+15% +$614K ﹤0.01% 3183
2018
Q3 		$5.95M Sell
736,604
-26,336
-3% -$188K ﹤0.01% 3164
2018
Q2 		$5.36M Buy
762,940
+18,996
+3% +$186K ﹤0.01% 3195
2018
Q1 		$10.6M Buy
743,944
+53,062
+8% +$563K ﹤0.01% 2802
2017
Q4 		$6.05M Buy
690,882
+87,103
+14% +$862K ﹤0.01% 3051
2017
Q3 		$7.06M Buy
603,779
+91,155
+18% +$1.12M ﹤0.01% 2974
2017
Q2 		$7.16M Buy
512,624
+102,700
+25% +$1.17M ﹤0.01% 2936
2017
Q1 		$5.62M Buy
409,924
+19,522
+5% +$203K ﹤0.01% 3017
2016
Q4 		$2.8M Buy
390,402
+97,478
+33% +$1.07M ﹤0.01% 3246
2016
Q3 		$4.44M Buy
292,924
+123,023
+72% +$1.62M ﹤0.01% 3064
2016
Q2 		$1.67M Buy
+169,901
New +$2.33M ﹤0.01% 3437

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Vanguard Group's SNDX Position: Q4 2025 in Review

Vanguard Group increased its Syndax Pharmaceuticals (SNDX) stake by 21% in Q4 2025, buying an estimated $19M and bringing the position to 6,230,334 shares worth $131M. The position accounts for ﹤0.01% of the portfolio, ranked #1745.

Vanguard Group first reported a position in SNDX in Q2 2016 and has held it in 39 quarters since. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

  • Vanguard Group held 6,230,334 shares of Syndax Pharmaceuticals worth $131M as of Q4 2025.
  • Vanguard Group bought 1,091,717 Syndax Pharmaceuticals shares in Q4 2025, an estimated $19M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1745 holding.
  • Vanguard Group first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 39 quarters since.
  • 229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.